Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorigenic assay

Biochemical Journal

Volumn 413, Issue 1, 2008, Pages 143-150

  Wegener, Dennis ^a,b,c   Hildmann, Christian ^a,b   Riester, Daniel ^a   Schober, Andreas ^b   Meyer Almes, Franz Josef ^d   Deubzer, Hedwig E ^c   Oehme, Ina ^c   Witt, Olaf ^c   Lang, Siegmund ^e   Jaensch, Martina ^f   Makarov, Vadim ^g   Lange, Corinna ^h   Busse, Benedikt ⁱ   Schwienhorst, Andreas ^a  

^a Institute for Microbiology and Genetics   (Germany)

^b ILMENAU UNIVERSITY OF TECHNOLOGY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d DARMSTADT UNIVERSITY OF APPLIED SCIENCES   (Germany)

^e TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^f ANALYTICON DISCOVERY GMBH   (Germany)

^g State Scientific Center of Antibiotics   (Russian Federation)

^h HANS KNÖLL INSTITUTE   (Germany)

ⁱ Zell kontakt GmbH   (Germany)

Author keywords

Chromone; Histone deacetylase like amidohydrolase (HDAH); Medium throughput screening; p benzoquinone; Pyran 4 one; Trifluoromethylketone

Indexed keywords

ACETYLATION; BIOACTIVITY; BIOCHEMISTRY; CELLS; CHEMOTHERAPY; ENZYMES; FOOD ADDITIVES; GENE EXPRESSION; LEAD; METABOLISM; MODEL STRUCTURES; ONCOGENIC VIRUSES; STABILIZERS (AGENTS); THROUGHPUT;

(SPM) CLASSES; ALCALIGENES; AMIDOHYDROLASE; ANTI-PROLIFERATIVE; CARCINOMA CELLS; CELL METABOLISM; EUKARYOTIC CELLS; GENERAL (CO); HISTONE ACETYLATION; HISTONE DEACETYLASE (HDAC) ACTIVITY; HISTONE DEACETYLASE (HDAC) INHIBITORS; HISTONE DEACETYLASES (HDAC); HISTONE H4; IN-VITRO; IN-VIVO; NEUROBLASTOMA (NB); POTENT INHIBITORS; SMALL MOLECULES; SUPPRESSOR GENES; THROUGHPUT SCREENING; TRANSCRIPTIONAL ACTIVITIES; TUMOUR CELLS;

TUMORS;

ACTINOMYCIN X; ANTINEOPLASTIC AGENT; BACTERIAL ENZYME; COMPOUND 22G03; COMPOUND 23F10; COMPOUND 33C08; COMPOUND 33D02; COMPOUND 40H03; COMPOUND 45E09; COMPOUND 46F08; COMPOUND 50B09; COMPOUND AN1; COMPOUND AN2; COMPOUND AN3; COMPOUND AN4; COMPOUND AN5; DACTINOMYCIN; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; HYDROLASE; PILOPLEURIN; ENZYME INHIBITOR; HISTONE DEACETYLASE;

ACETYLATION; ALCALIGENES; ARTICLE; BLADDER CARCINOMA; BORDETELLA; CARCINOMA CELL; CELL METABOLISM; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; EUKARYOTIC CELL; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; TUMOR CELL; TUMOR CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; DRUG ANTAGONISM; FLUORESCENCE; GENE EXPRESSION REGULATION;

ALCALIGENES; BORDETELLA; EUKARYOTA;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINATORIAL CHEMISTRY TECHNIQUES; ENZYME INHIBITORS; FLUORESCENCE; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; HUMANS; MOLECULAR STRUCTURE;

EID: 46249130572     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20080536     Document Type: Article

References (53)

1. Hildmann, C., Riester, D. and Schwienhorst, A. (2007) Histone deacetylases: an important class of cellular regulators with a variety of functions. Appl. Microbiol. Biotechnol. 75, 487-497
2. Davie, J. R. and Spencer, V. A. (2001) Signal transduction pathways and the modification of chromatin structure. Prog. Nucleic Acid Res. Mol. Biol. 65, 299-340
3. Mariadason, J. M., Corner, G. A. and Augenlicht, L. H. (2000) Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 60, 4561-4572
4. Peart, M. J., Smyth, G. K., van Laar, R. K., Bowtell, D. D., Richon, V. M., Marks, P. A., Holloway, A. J. and Johnstone, R. W. (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 102, 3697-3702
5. Monneret, C. (2005) Histone deacetylase inhibitors. Eur. J. Med. Chem. 40, 1-13
6. Moradei, O., Maroun, C. R., Paquin, I. and Vaisburg, A. (2005) Histone deacetylase inhibitors: latest developments, trends and prospects. Curr. Med. Chem. Anticancer Agents 5, 529-560
7. Minucci, S. and Pelicci, P. G. (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51
8. Riester, D., Hildmann, C. and Schwienhorst, A. (2007) Histone deacetylase inhibitors: turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. Appl. Microbiol. Biotechnol. 75, 499-514
9. Veale, C. A., Bernstein, P. R., Bohnert, C. M., Brown, F. J., Bryant, C., Damewood, Jr, J. R., Earley, R., Feeney, S. W., Edwards, P. D., Gomes, B. et al. (1997) Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase. J. Med. Chem. 40, 3173-3181
10. Frey, R. R., Wada, C. K., Garland, R. B., Curtin, M. L., Michaelides, M. R., Li, J., Pease, L. J., Glaser, K. B., Marcotte, P. A., Bouska, J. J. et al. (2002) Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett. 12, 3443-3447
11. Moreth, K., Riester, D., Hildmann, C., Hempel, R., Wegener, D., Schober, A. and Schwienhorst, A. (2007) An active site tyrosine residue is essential for amidohydrolase but not for esterase activity of a class 2 histone deacetylase-like bacterial enzyme. Biochem. J. 401, 659-665
12. Hildmann, C., Ninkovic, M., Dietrich, R., Wegener, D., Riester, D., Zimmermann, T., Birch, O. M., Bernegger, C., Loidl, P. and Schwienhorst, A. (2004) A new amidohydrolase from Bordetella or Alcaligenes strain FB188 with similarities to histone deacetylases. J. Bacteriol. 186, 2328-2339
13. Nielsen, T. K., Hildmann, C., Dickmanns, A., Schwienhorst, A. and Ficner, R. (2005) Crystal structure of a bacterial class 2 histone deacetylase homologue. J. Mol. Biol. 354, 107-120
14. Hildmann, C., Wegener, D., Riester, D., Hempel, R., Schober, A., Merana, J., Giurato, L., Guccione, S., Nielsen, T. K., Ficner, R. and Schwienhorst, A. (2006) Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. J. Biotechnol. 124, 258-270
15. Riester, D., Wegener, D., Hildmann, C. and Schwienhorst, A. (2004) Members of the histone deacetylase superfamily differ in substrate specificity towards small synthetic substrates. Biochem. Biophys. Res. Commun. 324, 1116-1123
16. Wegener, D., Hildmann, C., Riester, D. and Schwienhorst, A. (2003) Improved fluorogenic histone deacetylase assay for high-throughput-screening applications. Anal. Biochem. 321, 202-208
17. Wegener, D., Wirsching, F., Riester, D. and Schwienhorst, A. (2003) A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem. Biol. 10, 61-68
18. Zhang, J. H., Chung, T. D. and Oldenburg, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73
19. Deubzer, H. E., Ehemann, V., Westermann, F., Heinrich, R., Mechtersheimer, G., Kulozik, A. E., Schwab, M. and Witt, O. (2008) Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. Int. J. Cancer 122, 1891-1900
20. Cook, J. A. and Mitchell, J. B. (1989) Viability measurements in mammalian cell systems. Anal. Biochem. 179, 1-7
21. Witt, O., Monkemeyer, S., Ronndahl, G., Erdlenbruch, B., Reinhardt, D., Kanbach, K. and Pekrun, A. (2003) Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 101, 2001-2007
22. Riester, D., Hildmann, C., Schwienhorst, A. and Meyer-Almes, F. J. (2007) Histone deacetylase inhibitor assay based on fluorescence resonance energy transfer. Anal. Biochem. 362, 136-141
23. Jung, M. (2001) Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. 8, 1505-1511
24. Nielsen, T. K., Hildmann, C., Riester, D., Wegener, D., Schwienhorst, A. and Ficner, R. (2007) Complex structure of a bacterial class 2 histone deacetylase homologue with a trifluoromethylketone inhibitor. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 63, 270-273
25. Pashkevich, K. I., Sevenard, D. V. and Khomutov, O. G. (1999) Reactions of 2-polyfluoroacylcyclohexanones with 1,2-diaminoarenes. Russ. Chem. Bull. 48, 557-560
26. Asmer, H.-J., Lang, S., Wagner, F. and Wray, V. (1988) Microbial production, structure elucidation and bioconversion of sophorose lipids. J. Am. Oil Chem. Soc. 65, 1460-1466
27. Matsumoto, M., Matsutani, S., Sugita, K., Yoshida, H., Hayashi, F., Terui, Y., Nakai, H., Uotani, N., Kawamura, Y., Matsumoto, K. et al. (1992) Depudecin: a novel compound inducing the flat phenotype of NIH3T3 cells doubly transformed by ras- and src-oncogene, produced by Alternaria brassicicola. J. Antibiot. 45, 879-885
28. Privalsky, M. L. (1998) Depudecin makes a debut. Proc. Natl. Acad. Sci. U.S.A. 95, 3335-3337
29. Brakemeier, A., Lang, S., Wullbrandt, D., Merschel, I., Benninghoven, A., Buschmann, N. and Wagner, F. (1995) Novel sophorose lipids from microbial conversion of 2-alkanols. Biotechnol. Lett. 17, 1183-1188
30. Avramenko, L. G., Sklyar, Y. E., Perel'son, M. E. and Pimenov, M. G. (1975) The structure of pilopleurin: a new chromone from Pilopleura kozo-poljanskii. Chem. Nat. Compd. 9, 15-16
31. Tan, C. T., Dargeon, H. W. and Burchenal, J. H. (1959) The effect of actinomycin D on cancer in childhood. Pediatrics 24, 544-561
32. Shiba, S. (1959) Studies on the therapy of reticulosarcoma(-tosis) with actinomycin. Acta Unio Int. Cancrum 15, 264-266
33. Makarov, V. A., Riabova, O. B., Granik, V. G., Dahse, H. M., Stelzner, A., Wutzler, P. and Schmidtke, M. (2005) Anti-coxsackievirus B3 activity of 2-amino-3-nitropyrazolo[1,5-alpyrimidines and their analogs. Bioorg. Med. Chem. Lett. 15, 37-39
34. Forsberg, E. C., Downs, K. M., Christensen, H. M., Im, H., Nuzzi, P. A. and Bresnick, E. H. (2000) Developmentally dynamic histone acetylation pattern of a tissue-specific chromatin domain. Proc. Natl. Acad. Sci. U.S.A. 97, 14494-14499
35. Marks, P. A. and Breslow, R. (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25, 84-90
36. Marks, P., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T. and Kelly, W. K. (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194-202
37. Walter, M. W., Felici, A., Galleni, M., Soto, R. P., Adlington, R. M., Baldwin, J. E., Frère, J.-M., Gololobov, M. and Schofield, C. J. (1996) Trifluoromethyl alcohol and ketone inhibitors of metallo-β-lactamases. Bioorg. Med. Chem. Lett. 6, 2455-2458
38. Christians, F. C. and Loeb, L. A. (1996) Novel human DNA alkyltransferases obtained by random substitution and genetic selection in bacteria. Proc. Natl. Acad. Sci. U.S.A. 93, 6124-6128
39. Cameotra, S. S. and Makkar, R. S. (2004) Recent applications of biosurfactants as biological and immunological molecules. Curr. Opin. Microbiol. 7, 262-266
40. Isoda, H., Shinmoto, H., Kitamoto, D., Matsumura, M. and Nakahara, T. (1997) Differentiation of human promyelocytic leukemia cell line HL60 by microbial extracellular glycolipids. Lipids 32, 263-271
41. Isoda, H., Kitamoto, D., Shinmoto, H., Matsumura, M. and Nakahara, T. (1997) Microbial extracellular glycolipid induction of differentiation and inhibition of the protein kinase C activity of human promyelocytic leukemia cell line HL60. Biosci. Biotechnol. Biochem. 61, 609-614
42. Scholz, C., Mehta, S., Bisht, K., Guilmanov, V., Kaplan, D., Nicolosi, R. and Gross, R. (1998) Bioactivity of extracellular glycolipids: investigation of potential anti-cancer activity of sophorolipids and sophorolipid-derivatives. Proc. Am. Chem. Soc. Polym. Prepr. 39, 168-169
43. Gross, R. A., Bisht, K. S., Scholz, C., Mehta, S., Guilmanov, V. and Nicolosi, R. (1998) Treatment of cancer with chemically-modified sophorolipids, U.S. Pat. Application 60/092,446
44. Sudo, T., Zhao, X., Wakamatsu, Y., Shibahara, M., Nomura, N., Nakahara, T., Suzuki, A., Kobayashi, Y., Jin, C., Murata, T. and Yokoyama, K. K. (2000) Induction of the differentiation of human HL-60 promyelocytic leukemia cell line by succinoyl trehalose lipids. Cytotechnology 33, 259-264
45. Isoda, H., Shinmoto, H., Matsumura, M. and Nakahara, T. (1995) Succinoyl trehalose lipid induced differentiation of human monocytoid leukemic cell line U937 into monocyte-macrophages. Cytotechnology 19, 79-88
46. Aono, T. and Mizuno, K. (1988) Chromone derivatives useful as antitumor agents, U.S. Pat. 4,904,690
47. Boumendjel, A., Nicolle, E., Moraux, T., Gerby, B., Blanc, M., Ronot, X. and Boutonnat, J. (2005) Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2). J. Med. Chem. 48, 7275-7281
48. Semba, S., Itoh, N., Ito, M., Youssef, E. M., Harada, M., Moriya, T., Kimura, W. and Yamakawa, M. (2002) Down-regulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG hypermethylation in human colorectal carcinoma. Clin. Cancer Res. 8, 3824-3831
49. Liu, X. Y., Chen, H. and Patel, D. V. (1991) Solution structure of actinomycin-DNA complexes: drug intercalation at isolated G-C sites. J. Biomol. NMR 1, 323-347
50. Yu, C. and Tseng, Y. Y. (1992) NMR study of the solution conformation of actinomycin D. Eur. J. Biochem. 209, 181-187
51. Yu, F. L. (1980) Selective inhibition of rat liver nuclear RNA polymerase II by actinomycin D in vivo. Carcinogenesis 1, 577-581
52. Ross, W. E. and Bradley, M. O. (1981) DNA double-stranded breaks in mammalian cells after exposure to intercalating agents. Biochim. Biophys. Acta 654, 129-134
53. Wu, M. H. and Yung, B. Y. (1994) Cell cycle phase-dependent cytotoxicity of actinomycin D in HeLa cells. Eur. J. Pharmacol. 270, 203-212